Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection

  • Clin Gastroenterol Hepatol. 2020 Dec;18(13):3043-3045.e1. doi: 10.1016/j.cgh.2019.09.038.
Hye Won Lee  1 ,  Jun Yong Park  1 ,  Taegon Hong  2 ,  Min Soo Park  3 ,  Sang Hoon Ahn  4
Affiliations
  • 1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea; Yonsei Liver Center, Severance Hospital, Seoul, Korea.
  • 2. Department of Clinical Pharmacology, Yonsei University College of Medicine, Seoul, Korea; Clinical Trials Center, Severance Hospital, Seoul, Korea.
  • 3. Department of Clinical Pharmacology, Yonsei University College of Medicine, Seoul, Korea; Clinical Trials Center, Severance Hospital, Seoul, Korea; Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
  • 4. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea; Yonsei Liver Center, Severance Hospital, Seoul, Korea; Clinical Trials Center, Severance Hospital, Seoul, Korea. Electronic address: [email protected].
PMID: 31589980 DOI: 10.1016/j.cgh.2019.09.038
Abstract

The mechanism of action of hepatitis B immunoglobulin (HBIG) for chronic hepatitis B (CHB) treatment is not fully understood. A clinical trial in Japan suggested that HBIG therapy might benefit patients with CHB.1 Lenvervimab, a recombinant monoclonal HBIG developed by GC Pharma (Yongin, South Korea), has been screened from an anti-HBs-enriched phage-display library cloned from hepatitis B vaccine-boosted human blood cells and was produced in Chinese hamster ovary cells.2-4.

Products